The role of amylin receptor components in body weight and food intake control in obese knockout mouse models by Arrigoni, Soraya








The role of amylin receptor components in body weight and food intake
control in obese knockout mouse models
Arrigoni, Soraya





Arrigoni, Soraya. The role of amylin receptor components in body weight and food intake control in
obese knockout mouse models. 2020, University of Zurich, Vetsuisse Faculty.
Institut für Veterinärphysiologie  
der Vetsuisse-Fakultät Universität Zürich 
 
Direktor: Prof. Dr. med. vet. Max Gassmann 
 
Arbeitsgruppe: Prof. Dr. med. vet. Thomas Lutz 
 
 
Arbeit unter wissenschaftlicher Betreuung von 
Dr. Christelle Le Foll 
 
 
The role of amylin receptor components in body weight and food intake control in 






zur Erlangung der Doktorwürde der 








von Lugano, Switzerland 
 
 
genehmigt auf Antrag von 
 
Prof. Dr. med. vet. Thomas Lutz, Hauptreferent 





































Table of content 
 
SUMMARY (ZUSAMMENFASSUNG; ENG)       4 
 
ZUSAMMENFASSUNG          5 
 
1 INTRODUCTION          6 
1.1 Definition of obesity          6 
1.2 Control of food intake   7 
1.3 Control of energy homeostasis and energy metabolism   8 
1.4 Amylin  9 
1.4.1 Amylin secretion and function  9 
1.4.2 Amylin as adiposity signal 10 
1.4.3 Amylin receptors        11 
1.4.4 Brain expression of amylin receptors and amylin brain signaling  12 
1.4.5 Amylin agonist, obesity and diabetes: possible clinical targets  13 
 
2 AIM AND HYPOTHESIS        14 
  
3 MATERIALS AND METHODS       16 
3.1 Mice and Husbandry         16 
3.2 Experimental diet         16 
3.3 Genotyping          17 
3.3.1 RAMP 3 WT and KO mice genotyping     17 
3.3.2 RAMP 1 WT and KO mice genotyping     18 
3.4  Food intake, body weight and non-fasted blood glucose level during 20 weeks on 
high fat diet 45%         19 
3.5 Handling and acclimatization                  19 
3.6 Peptides          19 
3.7 Mice treatment         19 
3.8 Measurement of body composition      20 
3.9 Biochemical analysis        20 
3.10 Statistical analysis         22 
 
4
4 RESULTS           23 
4.1 RAMP 1/3 wild-type and double knockout mice     23 
4.1.1 Obesity induction period       23 
4.1.2 Effect of amylin-selective agonist NN1213and sCT in RAMP1/3 WT and 
KO models on body weight, food intake and blood parameter after 21 days of 
treatment 25 
4.1.3 Effect of amylin-selective agonist NN1213 and sCT in RAMP1/3 WT and KO 
models on body composition and blood parameters                           27 
4.2 RAMP 3 wild-type and knockout mice      30 
4.2.1 Obesity induction period       30 
4.2.2 Effect of amylin-selective agonists NN1213 and sCT in RAMP3 WT and KO 
mice models on body weight, food intake and blood parameter after 21 days of 
treatment                     31 
4.2.3 Effect of amylin-selective agonist NN1213 and sCT in RAMP3 WT and KO 
mice on blood glucose level                                                                                       33 
4.3 RAMP 1 mild-type and knockout mice       34 
4.3.1 Obesity induction period       34 
4.3.2 Effect of amylin-selective agonist NN1213 and sCT in RAMP 1 WT and 
KO mice models on body weight, food intake and blood parameter after 21 
days of treatment  35 
 
5 DISCUSSION          38 
5.1 Effect of 20 weeks 45% high fat diet on body weight and food intake in RAMP 
mice                      38 
5.2 Treatment          39 
5.2.1 RAMP 1/3         39 
5.2.2 RAMP 3          40 
5.2.3 RAMP 1          41 
5.3 Comparison between the 3 WT and KO mice models    41 
5.4. Limitation of the study        42 
5.4.1 Differences between rats and mice      42 
5.4.2 Role of RAMP 2        43 




6 REFERENCES          46 
7 AKNOWLEDGEMENTS 
8     CURRICULUM VITAE       
6
  Summary 
Zusammenfassung (Englisch) 
Soraya Arrigoni 
Vetsuisse-Faculty, Unversity of Zurich 2020 
E-mail: dekanat@vetadm.uzh.ch 
 
The role of amylin receptor components in body weight and food intake control in obese 
knockout mouse models 
 
Obesity currently affects over one third of the entire world’s population. The treatment of 
obesity and overweight is one of the most challenging topics in medicine and numerous 
approaches can be used to fight this expanding problematic. 
 
The aim of this study was to assess the weight loss efficacy of the amylin selective agonist 
(NNCO1741213 abbreviated to NN1213) in the three RAMP KO mouse models, RAMP 1/3 
RAMP 3 and RAMP 1 WT/KO, compared to that of salmon calcitonin (sCT) 
Our results show that RAMP 1 or RAMP 3 are necessary for the action of NN1213 in mice. 
Both receptor isoforms mediate the action of amylin selective agonists on body weight and 
food intake. In fact, we saw a positive effect of NN1213 to lower body weight in all WT mice 
and in the mice, where at least one RAMP was expressed. NN1213 decreased food intake and 
body weight in these mice. Further, we provided evidence that subchronic sCT treatment in 
mice decreases body weight and food intake only in the absence of RAMP 3. In addition to 
that, our results suggest that subchronic sCT does not have any effect on food intake and body 
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Die Rolle von Amylinrezeptoren in der Kontrolle des Körpergewicht und der 
Nahrungsaufnahme in adipösen Knockout-Mausmodellen 
 
Ziel der Arbeit war es, die Effekte des Amylin-selektiven Agonisten NNCO1741213 
(NN1213) auf das Körpergewicht und auf die Futteraufnahme während einer 21 Tage langen 
Therapie von WT und RAMP 1/3; RAMP 3 und RAMP 1 KO Mäusen im Vergleich zu den 
Effekten von Salmon Calcitonin (sCT) zu untersuchen. Zusätzlich wollten wir die Rolle der 
verschiedene RAMPs in der Pharmakologie des Amylin-selektiven Agonisten (NN1213) und 
des Dual-amylin-calcitonin-receptor Agonist (auch DACRA genannt) sCT analysieren.  
Wir konnten zeigen, dass RAMP 1 oder RAMP 3 für die Wirkung von NN1213 eine Rolle 
spielt. Beide Rezeptor-Isoformen vermitteln die Wirkung des Amylin Agonisten NN1213 auf 
das Körpergewicht und auf die Futteraufnahme. NN1213 hatte einen positiven Effekt auf das 
Körpergewicht bei allen WT Mäusen und bei Mäusen, bei denen zumindest einer der beiden 
RAMPs exprimiert war.  
Zusätzlich lieferten wir den Hinweis darauf, dass eine subchronische sCT Verabreichung bei 
Mäusen nur in Abwesenheit von RAMP 3 wirkt. Ergänzend dazu deuten unsere Resultate 











1.1. Definition of obesity 
 
The World Health Organization defines obesity and overweight as abnormal or excessive fat 
accumulation relative to lean mass. To assess body condition of a person, body mass index 
(BMI) is usually used; the BMI is the weight in kilograms divided by the square of his/her 
height in meters (kg/m
2
). An adult is considered as overweight with a BMI greater or equal to 
25 kg/m
2 
and as obese with a BMI greater or equal to 30 kg/m
2
.  
Obesity, along with overweight, currently affects over one third of the entire world’s 
population. While the prevalence of obesity in adults seems to be stable in developed 
countries, the prevalence of global childhood obesity and the prevalence of adult obesity in 
developing countries is constantly increasing
1
.  
Obesity per se is the result of an imbalance between calories consumed and calories 
expended
1
, this difference creates a positive energy balance which results in excess in body 
weight.  




Obesity and overweight may lead to several health problems. In fact, they are risks factor for 




The treatment of obesity and overweight is one of the most challenging topics in medicine and 
numerous approaches can be used to fight this expanding problematic. However, many of the 
possibilities to manage this worldwide disease seem to fail. Changes in lifestyle, such as 
consuming less calories and increasing physical activity to burn more calories represent the 
most obvious and least invasive ways to decrease body weight
3
. Since changes in lifestyle are 
often neither acceptable nor satisfactory in the longer term, new alternatives to reduce body 
weight such as combination of hormones therapy or bariatric surgery intervention have been 
developed. However, bariatric surgery is invasive, expensive and reserved for patients that are 
critically obese. Unfortunately, most of the pharmacological treatment that were developed 
until recently are not satisfying in the long-term weight loss. Thus, new therapies need to be 
developed approaches, in terms of understanding the peripheral and central control of food 





1.2. Control of food intake 
 
A complex system of central and peripheral signaling
4
 is involved in the physiological control 
of food intake. Of predominant interest are peripherally produced hormones, which are 
considered physiological controls of eating. Two groups can be distinguished: the first one 
includes satiation signals, considered “short-term” signals, such as cholecystokinin (CKK), 
amylin, peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) secreted during a meal by 
the pancreas and intestine
5
. They stimulate the hindbrain directly or indirectly via sensory 
neuronal pathways
6
 and thus regulate the two meal-related processes: satiation and satiety 
(Figure 1).  
The second group comprises adiposity signals that reflect the body’s fat stores. The 




, secreted by the 
pancreatic β-cells, and leptin
9
 secreted  by the adipocytes proportionally to the amount of fat 
mass. Together, they control long-term energy homeostasis. Leptin is mainly secreted from 
subcutaneous fat tissues
10
, while insulin secretion is mostly related to the amount in visceral 
fat
10
 (Figure 1). 
 
These peptides act on the brain to control food intake and different aspects of energy 
metabolism. 
This thesis will focus on the role of amylin in particular and its different functions are 





Figure 1: Interaction of different hormones affecting peripheral and central signaling to 
control food intake
11
. Abbreviations: PP, pancreatic polypeptide; PYY, Peptid YY; GLP-1, 
Glucagon-like Peptide 1; OXM, Oxyntomodulin; CKK, Cholecystokinin 
 
1.3. Control of energy homeostasis and energy metabolism 
 
Body fat mass and body composition reflect three processes of energy homeostasis: energy 
intake, energy storage and energy expenditure. Energy homeostasis is achieved when caloric 
intake equals energy use and dissipation, and this dynamic balance maintains body weight 
constant over long period of time. A chronic imbalance between energy expenditure and 
caloric intake can result in a surplus of energy, which will be stored as body fat mass, or lead 
to body weight loss, when energy consumption exceeds energy intake.  
Neuronal, endocrine and metabolic signals are involved in the control of energy homeostasis 
and thus in the development of obesity
12
. The hormones and peptides that control meal-to-
meal food intake (satiation or satiety signals) and adiposity signals play the crucial role in the 
11
control of food intake and thus in the regulation of energy homeostasis
6
. These hormones and 
particularly amylin, once secreted, are transported from the periphery via the blood to activate 
specific brain areas. Amylin activates neurons located in circumventricular organs such as the 
area postrema (AP) which does not have a blood brain barrier
13




In rodents, as in humans, the energy expenditure is in part regulated through the thermogenic 
activity of the brown adipose tissue (BAT)
14
, which is at the same time controlled by the 
sympathetic nervous system
14
. Recent studies indicate that amylin is able to increase BAT 
activity. In fact, mice that overexpress human RAMP1 (receptor activity modifying protein-1, 
a key component of functional amylin receptor) in neurons are lighter, have less fat and 
increased energy expenditure compared to the control animals
15
. Amylin is also responsible 
for increasing the sympathetic nerve activity, thus enhancing energy expenditure by the 
BAT
16
. Further, a previous study demonstrated that administration of a long actin selective 





1.4. Amylin  
 
1.4.1. Amylin secretion and function 
 
Amylin is a centrally acting 37-amino acid hormone mainly co-produced and co-secreted with 
insulin by beta cells of the pancreas when triggered by nutrient influx in the gastrointestinal 
tract
18




Amylin has physiologically important and complementary roles with insulin in the regulation 
of nutrient fluxes
20
. Indeed, amylin suppresses glucagon release from the pancreas, inhibits 
gastric acid secretion and slows gastric emptying
21
. Amylin plays a role in the control of meal 
size: it reduces eating by inducing satiation, which is the promotion of meal-ending processes 
(Figure 2). Thus, in response to nutrient consumption, circulating amylin concentration in rats 
rises rapidly from a range of 3-5 pM in the fasting state to postprandial concentration of 15-25 
pM
14
 and it has been shown that administration of exogenous amylin peripherally reduces 
eating  and meal size within minutes
14
, while having no effect on the subsequent inter-meal 
interval
22
. In a pharmacological use, the desired effect of amylin’s action is to decrease blood 
glucose, associated with long-term loss of body weight
14
. It is important to note, that amylin 
12
and its analogs are able to reduce meal size inducing satiation, without producing any signs of 











1.4.2. Amylin as adiposity signal 
 
Adiposity signals are hormones that are secreted in proportion to body fat
23
. As mentioned 
above, increased blood levels of these hormones are suggestive of a higher amount of body 
fat
13
 and are thought to affect eating processes by enhancing the effects of satiation signals
14
. 
In fact, an increase in basal insulin or leptin suggests a gain in body weight which 
subsequently induces a lower consumption of food to restore a lower body weight at least in 
insulin and leptin-sensitive individual
24
.  
Chronic administration of adiposity signals in normal-weight individuals causes decrease in 
food intake and loss of body fat, while obese individuals are often resistant to these signals. 
Thus, while the obese state is characterized by hyperinsulinemia and hyperleptinemia
13
, it is 
also characterized by insulin and leptin resistance
13
, which challenges their therapeutic 
13
usefulness. Like insulin and leptin, a similar role is played by amylin with basal amylin levels 
being directly proportional to body fat
25
. Indeed, elevated levels of fasting amylin are found in 
obese individuals compared to normal-weight individuals
26, 25





 amylin administration decreases food intake and body weight, 
resulting in a reduction of fat depots
29
. More specifically, previous studies proved that 
peripherally administered amylin is able to induce body weight loss, reducing food intake and 




Additionally, chronic administration of 
amylin antagonists increases food intake
31





1.4.3. Amylin receptors 
 
The peptides calcitonin (CT), calcitonin gene related peptide (CGRP), adrenomedullin (AM), 
amylin and adrenomedullin 2/intermedin (AM2/IMD) set up a family of closely related 
peptides
32
. In terms of amino acid sequence, amylin is most closely related to calcitonin gene 
related peptide (CGRP)
14
. In all peptides, key structural features are shared and conserved, 
including a N-terminal ring structure formed by a di-sulfide bond a C-terminal amide
33
.  
Their receptors comprise a CT receptor (CTR) or a calcitonin-like (CL) receptor (CLR) core 
combined with one of the three receptor activity-modifying proteins (RAMPs). The CLR by 
itself is not able to reach the cell surface in any remarkable amount and does not respond to 
any known ligand
32
.  To function normally, CLR needs to bind either to RAMP1, RAMP2 or 
RAMP3. With RAMP1 it becomes CGRP receptor; associated with RAMP2 and RAMP3 it 
converts to AM1 (CLR/RAMP2) and AM2 (CLR/RAMP3)
32
 (Figure 3).   
The CTR by itself shows high affinity to CT; but when associated with one of the three 
RAMPs, giving AMY1, AMY2 and AMY3 receptors
32
, these receptors have a higher affinity 
to amylin
33,14
 (Figure 3). Differently from CLR, CTR itself can reach the cell surface and be 
expressed, so it is likely that mixed populations of CTR/RAMP complexes and CTR alone 
will be found in the different brain expression sites. This makes it very arduous to clarify the 
action of specific CT and AMY receptors
32
.  Additionally, it is important to say that no 
receptor subtype specific antagonists are available and that the complex between CTR and 
RAMP2 is extremely difficult to observe since RAMP2 KO is a lethal mouse model and 








Figure 3.  Composition and classification of human calcitonin-family receptors. 
The legend in the box shows core protein receptors, ligands and receptor modifying proteins. 
Ligands are illustrates as spheres; relative sizes reflect the corresponding potency at each 
receptors; smaller sphere indicates lower potency and longer sphere indicates higher potency 




1.4.4. Brain expression of amylin receptor and amylin brain signaling 
 
CTR and RAMPs are expressed in the area postrema (AP), in the nucleus of the solitary tract 
(NTS), in the lateral hypothalamic area, in the ventromedial (VMH) and arcuate (ARC) 
hypothalamic nuclei and in the ventral tegmental area
34
. Several studies have demonstrated 
that amylin’s action depends mainly and directly on an activation of the AP, which contains a 
high density of amylin receptors
35, 20 36, 37,38 
including all the components such as CTR, 
RAMP1 and RAMP3
39, 40
; the direct stimulation of AP neurons is possible because of a lack 
of a functional blood-brain barrier in this area
41
. To investigate the specific intracellular 
signaling mechanism of amylin, neuronal activation markers such as c-Fos are used. c-Fos is 
an early gene product which is expressed in brain areas activated by amylin and detected with 
immunohistochemistry
42, 38, 43, 44
.  With this neuronal marker, it is possible to detect also 
secondary brain areas stimulated by amylin, including the NTS and the lateral parabrachial 
nucleus (LPB), which then transfer the neural signals to other hypothalamic nuclei
14
 (Figure 
4). Despite the widespread use of c-Fos, it is important to say that the exact role of the latter 
for amylin’s behavioral effects is still unclear: it is only a marker of activation of different 
15
brain areas. Therefore the precise signaling pathway of amylin that is necessary for its eating 






Figure 4. Overview of the neuronal signaling induced by amylin and its interaction with other 
hormones. Amylin reaches the AP via the blood circulation and activates AP neurons that 
project to area such as NTS and LPB
14
. Abbreviations VMH, ventromedial nucleus of the 
hypothalamus; ARC, arcuate nucleus; E2, estradiol 
 
1.4.5. Amylin agonist, obesity and diabetes: possible clinical targets 
 
Amylin receptors are clinical targets for diabetes and obesity
45
. Many studies have assessed 
the effect of pramlinitide, a soluble analog of human amylin, that is currently the only 
approved amylin based drug (Symlin 
R
) to treat diabetes type 1 and type 2. Indeed these 
studies have shown that amylin analogues could also be useful for the treatment of obesity, 
especially in combination with other agents
46,47
 such as metformin by decreasing food intake, 
meal size and eliciting a fat-specific reduction in body weight
46
. Amylin combined with leptin 
seems to be the most promising and clinically relevant therapeutic combination for obesity. In 
fact, amylin can improve leptin sensitivity and leptin resistance in obesity can be overridden 
by amylin
48
. However, new amylin receptor agonists with improved potency and 
pharmacokinetics may provide better therapeutics for the treatment of overweight and obesity.  
 
Davalintide, an amylinomimetic with increased potency, efficacy and duration of action 
seems to exhibit more potency at the CGRP receptor than amylin, but binds similarly to 
amylin receptor as amylin does. Davalintide shows more potency than amylin in reducing 
food intake and body weight in rats
49
. Thus, davalintide shares similarity in the 
16
pharmacokinetics with salmon calcitonin (sCT) (see below). However, its mode of action 
appears to be similar to amylin: both are able to reduce intake of palatable diet and both 




sCT is a natural dual amylin-calcitonin receptor agonist known as DACRA. It is able to 
activate both AMY and CT receptors
19
, but not CGRP receptors
50
. Compared to amylin, sCT 
has a much longer duration of action, which leads to prolonged effects. Different studies have 
shown that sCT may be a potential treatment for some metabolic disorders: in fact, it elicits 
body weight loss, elevates energy expenditure, controls food intake and improves glucose 
metabolism in rats
51, 52, 53, 54
.  
 
Based on these findings, several dual amylin and calcitonin receptors agonist have been 
described. The most investigated compounds, known by “KBP” codes, are KBP-042, KBP-
088 and KBP-089
50, 55, 56
. These compounds present the potency of sCT, whilst increasing 
their tolerability in rats
56
. The pharmacology of these molecules, at the level of the receptor, 
has not been extensively studied yet: it has only been shown that they stimulate, similar to 
sCT, both AMY3 and CT receptors, but not CGRP receptors
32
. Furthermore, the 
pharmacology at other AMY receptors is not yet characterized; this makes it difficult to 
understand their receptor potency and their mechanism of action. Additional analyses are 







2. Aims and hypotheses 
  
The primary focus of our research was to investigate the role of RAMPs in modulating the 
pharmacological effects and potential differences of the dual amylin and calcitonin receptor 
agonists sCT in comparison to an amylin selective analogue, NN1213, on food intake and 
body weight. To assess these effects, single and double RAMP KO mice models were used. 
It is important to note that most published data on the anti-obesity effects of amylin and 
calcitonin agonist are based on rat models and not on mice models. Published data from Novo 
Nordisk indicate that diet-induced obese mice respond differently to both amylin and sCT 
analogues than obese rats. Indeed, mice seem to be resistant to the effect of subchronic sCT 
on food intake and body weight while rats are not. Hence, using RAMP KO mice models, we 
aimed at understanding these differences.  
 
Novo Nordisk synthetized and characterized a long actin amylin selective analogue 
(NN1213), which will be more suitable to use in comparison to sCT. 
 
Hypothesis:  
The amylin-selective agonist NN1213 acts via RAMP 1 and/or RAMP 3 to elicit weight loss 
while sCT can elicit weight loss in the absence of RAMP 1 and or RAMP 3 in mice. 
  
18
3. Material and methods	
 
3.1. Mice and Husbandry 
 
RAMP 1 KO, RAMP 3 KO and RAMP 1/3 double knockout (KO) mice on a 129s2/SvEv 
background were kindly provided by Kathleen Caron of the Department of Cell Biology and 
Physiology, University of North Carolina, USA. 
Mice imported from the USA were rederived by the Institute of Laboratory Animal Science 
by embryo transfer for hygiene reason and transferred to the LASC-NGZ facility. 
RAMP1/3 KO were maintained on a KO breeding scheme while RAMP 1KO and 3KO were 
bred my mating heterozygous mice.  RAMP 3 WT mice also served as WT controls for the 
RAMP 1/3 KO mice. 
 
Male mice were housed in an environment maintained at 21 ±2°C, under a 12/12 hour light-
dark cycle (lights off at 19.00 h). Mice had ad libitum access to standard chow (Kliba 3436, 
3.14 kcal/g of food) and water, until the age of approximately 4 weeks. Then mice were 
maintained on 45% fat high fat diet (HFD, D12451 Research Diet, 4.73 kcal/g of food, New 
Brunswick, NJ, USA) ad libitum from approximately 4 to 25 weeks of age to induce obesity. 
The same diet was then continued during the 21-day treatment period. The mice were group 
housed (2/3 mice per cage) until 12 week of age, when they were single housed into T2L 
cages due to aggressive behavior. Each cage was furnished with a red plastic house and nest-
building material and wood shaving. 
 
All procedures involving animals and their care were approved by the Veterinary Office of 
the Canton of Zurich, Switzerland, and in accordance with the EU Directive on the protection 
of animals used for scientific purposes. 
 
3.2. Experimental diet 
 
For the entire experiment, mice were maintained on a 45% HFD (Diet D12451, Research 














3.3.1. RAMP 3 WT and KO mice genotyping  
 
RAMP 3 WT and KO mice were genotyped at the age of 3-4 weeks by PCR analysis of toe 
DNA. Briefly, 200 µl lysis buffer (50 mM NaOH) were added per biopsy and every tube was 
incubated at 95° C and shaken at 800 rpm for 35 min. After that, 200 µl of neutralization 
buffer (500 mM Tris-HCL) was added per biopsy and underwent PCR.  
 
Genotype was determined using the following primers (Microsynth AG, Balgach, 
Switzerland): 
• RAMP3 R3-1- 5’-GTGCTCAAGGGTTCTGTCTG-‘3, 
• RAMP3 R3-10-5’-GACCTGGTTCATCTCTGGCTC-3’ 
• RAMP3 Neo6-10- 5’-GCTTCCTCTTGCAAAACCACA-3’  
 
We performed two different PCRs: one for the WT band detection and one for the KO band 
detection. For the WT PCR, 1 µl DNA of every biopsy was used and to each of them, we 
added 15.85 µl H2O, 5 µl green PCR buffer, 1 µl dNTPs, 1 µl R3-1, 1 µl R3-10 and 0.15 µl 
Go-Taq 5 u/µl mixed all in a same mastermix reaction. The protocol used for the WT PCR 
was the following: first cycle of 5 minutes at 95°C, after that 40 x cycles of 30 seconds at 
95°C, 30 seconds at 59°C and 90 seconds at 72°C and after that one last cycle of 10 minutes 
at 72°C.  
For the KO PCR we used 1 µl DNA of every biopsy and to each of them we added 15.85 µl 
H2O, 5 µl green PCR buffer, 1 µl dNTPs, 1 µl neo-60, 1 µl R3-10 and 0.15 µl l Go-Taq 5 u/µl 
mixed all in a same mastermix reaction. The protocol used for the KO PCR was the 
20
following: a cycle of 5 minutes at 95°C, after that 40 x cycles of 30 seconds at 95°C, 30 
seconds at 56°C and 90 seconds at 72°C and after that one last cycle of 10 minutes at 72°C. 
To detect and separate the PCR products, 100 ml 2% agarose gel with 4 ul gel red was 
prepared and for every sample 6 µl of WT reaction mix and 6 µl KO reaction mix were put 
side-by-side and gel electrophoresis was run for 40 min at 100V. Finally, the gel was 
photographed with Biorad Reader and the genotype was determined. The WT PCR produced 
a band of 650 bp while the KO PCR produced a 675 bp band.  
 
3.3.2. RAMP 1 WT and KO mice genotyping  
 
RAMP 1 WT and KO mice were genotyped at the age of 3-4 weeks by PCR analysis of toe 
DNA. 300 µl isolation buffer and 3.5 µl Proteinase K were added to mouse tissue in a 
microtube. The tubes were incubated at 95°C until tissue was dissolved. 600 µl of cold 100% 
ethanol were added per tube and the samples were then centrifuged at 14000 rpm for at least 2 
hours, the supernatants were poured off. The same was repeated for 30 seconds. Then the 
samples were dried at air for 10 minutes and resuspended in 100 µl of TE buffer or water. 
We performed one single PCR using the following primers: 
• Forward Primer: TCATGGGGACCTTTAGGTAAGC 
• Reverse Primer: ACAGCAATCCTTCTACCTCAACAC 
 
The protocol used for RAMP 1 genotyping was the following: 
PCR machine performed 1 cycle at 95°C for 5 minutes, 40 cycles at 95°C for 45 seconds, at 
59°C for 45 seconds and at 72°C for 90 seconds, 1 cycle at 72°C for 10 minutes and the last 
cycle at 22°C until use.  
We prepared 100 ml of 2% agarose gel with 4 µl gel red. 6 µl of each sample were put in the 
gel and gel electrophoresis was let run for 40 min at 100V. Finally, the gel was photographed 
with Biorad Reader and the genotype was determined. The WT PCR produced a band of 1600 
bp while the KO PCR produced a 400 bp band. 
 
3.4. Food intake, body weight and non-fasted blood glucose level during 20 weeks on 
45% high fat diet  
 
21
Weekly body weight and food intake were measured manually using a digital scale (Mettler 
Toledo x540025 Delta Rage scale). Blood was harvested from the tail and non-fasted glucose 
was measured using Contour Next Blood Glucose Meter (Bayer Consumer Care AG, Basel, 
Switzerland) one time every two weeks at 14.00 h, i.e. in the second half of the light phase. 
 
3.5. Handling and acclimation 
 
Prior to any testing, mice were given one week to acclimate to the daily injections to reduce 
stress. Mice were handled and injected subcutaneously in the neck once daily with 1 ml/kg 
saline solution. 1 ml sterile syringes (B. Braun Melsungen AB, Melsungen, Germany) and 




All in the experiment used drugs were provided from Novo Nordisk Pharma AG: 
• Vehicle: Buffer 9302, pH 4.0, 5 mM acetate, 249 nM propylene glycol, 0.007% 
Tween 20 
• NNCO1741213 (NN1213): 5 nmol/ml, 30 nmol/kg 
• salmon Calcitonin (sCT) 0186: 27.7 nmol/ml, 150 nmol/kg 
 
3.7. Mice chronic treatment and sacrifice 
 
At the age of 25 weeks and after 20 weeks on 45% HFD, male RAMP 1/3 KO, RAMP 1 KO 
and RAMP 3 KO and their respective WT male littermates were randomized by body weight 
and assigned to their treatment group (n=8/group):  
• WT vehicle;  
• WT NN1213, dose 30 nmol/kg;  
• WT sCT, dose 150 nmol/kg;  
• KO vehicle;  
• KO NN1213, dose 30 nmol/kg;  
• KO sCT, dose 150 nmol/kg.  
 
22
Mice were injected subcutaneously once a day for 21 days in the middle of the light phase 
between 11.00-12.00h. Prior to injection, daily body weight and food intake were measured 
manually using a digital scale (Mettler Toledo x540025 Delta Rage scale). 
 
At the end of treatment, animals were fasted for 2 hours during the light phase, sacrificed by 
exsanguinations under deep pentobarbital anesthesia (100 mg/kg, IP injection, Cantonal 
Pharmacy of Zurich, Switzerland). Blood was sampled using cardiac puncture into 1 ml 
EDTA tubes. Brains were removed, frozen on dry ice and stored at -80°C. The mice were 
sutured closed after exsanguination and stored at -20°C until body composition analysis was 
performed on the carcasses. To have comparable results with the rest of the study, tail blood 
glucose level was assessed using Contour Next Blood Glucose Meter (Bayer Consumer Care 
AG, Basel, Switzerland). 
 
3.8. Measurement of body composition 
 
Quantitative microcomputed tomography of WT mice and RAMP 1/3 KO was performed 
using La Theta LCT-100A (LaTheta LCT-100A scanner, Hitachi-Aloka Medical Ltd., Tokyo, 
Japan) on the carcasses of the animals placed supine in the plexiglass holder after sacrifice. 
The X-ray source tube voltage was set at 50 kV with 1 mA current. A sagittal image of the 
animal was used as an overview about the position of the animal, after that scans of the entire 
animals were done. To avoid artifacts, the legs were adequately extended. The region between 
the vertebrae L1-L6 was evaluated for lean and fat mass. Although the software LaTheta 
already automatically distinguished between visceral and subcutaneous fat, each image was 
manual examined and in some cases an image-by-image correction was required. Adipose 
tissue weights were then computed using the commonly used density factor of 0.92 g/cm
3
 to 




3.9. Biochemical analysis 
 
Prior to sampling, mice were food deprived for 2h. Blood samples were collected from the 
right ventricle of the heart from all animals during the sacrifice in 1ml EDTA-coated tubes 
containing DPP4 inhibitor (10 ul/1 ml blood) and proteinase inhibitor (P2414; Sigma Aldrich, 
30ul/1 ml blood) to stop the enzymatic degradation of peptide hormones, centrifuged at 12000 
rpm for 5 minutes at 4°C. Plasma was transferred to clean Eppendorf tubes and kept at -80°C 
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until further analysis. Plasma level of leptin, insulin, GLP-1 and glucagon were measured 
with 4 plex-Mouse Metabolic Biomarkers kit (MesoScale Discovery, Gaithersburg, MD, 
USA) according to the manufacturer’s instruction. 
3.10 Statistical analysis 
 
All analyses were performed using GraphPad Prism software for Mac OS X version 8.0 
(GraphPad, San Diego, CA). In experiment comparing independent treatment groups, 
significance was tested using one-way ANOVA. When more than one factor were compared, 
we used two-way ANOVA, followed by Sidak or Tukey’s multiple comparisons test as 
recommended. A P-value < 0.05 was considered statistically significant. All data are 






4.1.  RAMP 1/3   wild-type and double knockout mice 
 
4.1.1. Obesity induction period  
 
Male mice were 4 weeks-old when recruited for this experiment.  From 4 to 24 weeks old, 
mice body weight and food intake on 45% HFD was followed weekly (Figure 1).  
 
Baseline body weight was similar across both groups with no significant difference at the start 
of the experiment (16-17g). During the first 7 weeks, the body weight between these two 
genotype groups was not significantly different. From week 8 onward, RAMP 1/3 KO mice 
displayed a significantly lower body weight (p<0.05) compared to the WT cohort and it 
remained significantly lower until the end (Figure 5A). At the end of the obesity induction 
period, average body weight was 44g in the WT mice and 33.4g in the KO mice (Figure 1A). 
 
Although the two groups showed no significant difference in body weight gain during the first 
6 weeks on 45% HFD, RAMP 1/3 WT started to gain more weight than KO after 3 weeks on 
45% HFD which became significant at 11 weeks-old (Figure 5B).   
 
Furthermore, after 9 weeks on HFD, RAMP 1/3 WT mice ate significantly more than the 
double KO mice. In fact, cumulative food intake measured in RAMP 1/3 WT animals 
remained significantly higher compared to the double KO until the end of the HFD period 




Figure 5: Obesity induction period in RAMP 1/3 WT and KO mice fed with 45% HFD 
ad libitum for 20 weeks. A: Weekly body weight (g) in RAMP 1/3 WT and KO mice over 
20 weeks on 45% HFD.  B: Weekly body weight gain (g) in RAMP 1/3 WT and KO mice 
over 20 weeks on 45% HFD. C: Weekly cumulative food intake (kcal) of RAMP 1/3 WT and 
KO mice over 20 weeks on 45% HFD. D: Non-fasting blood glucose level (mmol/l) of 
RAMP 1/3 WT and KO mice maintained on 45% HFD for 20 weeks measured on a bi-weekly 
base.  All data are expressed as mean ± SEM, symbols denote significant differences between 
the two genotypes; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. N = 24 per group. 
 
 
Analysis of non-fasting tail blood glucose measured on a bi-weekly basis (Figure 5D) showed 
that baseline blood glucose level was similar across both groups with no significant difference 
before the start of the 45% HFD period.  
Then, for the entire HFD period, RAMP 1/3 WT displayed a higher blood glucose level than 
RAMP 1/3 KO mice after 2 weeks of HFD and between weeks 12 and 22 (Figure 5D). 


























































































































4.1.2. Effect of amylin-selective agonist NN1213 and sCT in RAMP 1/3 WT and 
KO mouse models on body weight, food intake and blood parameters after 




Figure 6: Effect of amylin-selective agonist NN1213 (30 nmol/kg) and sCT (150 
nmol/kg) subchronic treatment for 21 days in RAMP 1/3 WT and KO mice after an 
induction obesity period of 20 weeks on 45% HFD A: daily BW (g) of RAMP 1/3 WT and 
KO mice treated for 21 days with vehicle, NN1213 (30 nmol/kg) and sCT (150 nmol/kg). B: 
daily body weight gain (g) of RAMP 1/3 WT and KO mice treated daily with vehicle, 
NN1213 and sCT for a period of 21 days. C: daily food intake of RAMP 1/3 WT and KO 
mice during 21 days of treatment with vehicle, NN1213 and sCT. Data are represented as 
mean ± SEM. N= 8 per group. Parameters with differing superscript letters differ from each 
other at p<0.05 level by Sidak post hoc adjustment after significant intergroup differences 
were found by two-way ANOVA. Other statistical differences are indicated under each 
figure.  
 
After 20 weeks on 45% HFD, mice were randomized by body weight into 6 groups 
(n=8/group) and assigned to a specific treatment group.  
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Body weight of RAMP 1/3 WT and KO vehicle-treated groups didn’t show any intra-
genotype difference throughout the entire experiment and they continued to constantly gain 
weight. WT and double RAMP 1/3 KO animals had a significantly different baseline body 
weight and this difference in body weight remained significant until the end of the treatment 
period (Figure 2A).  
From day 1 to day 8, RAMP 1/3 WT injected with the amylin-selective agonist NN1213 
showed a marked weight loss (p<0.05, Figure 2B) and gained significantly less body weight 
from day 3 to day 6 in comparison to WT vehicle group (p<0.05, Figure 2B). After this initial 
significant effect, RAMP 1/3 WT NN1213-treated mice stopped responding to the treatment 
and regained weight until the end of treatment period. In comparison, RAMP 1/3 KO mice 
receiving the same dose of NN1213 lost no weight in the first treatment days and continued 
to gain weight throughout the treatment period (Figure 2A, B).  
RAMP 1/3 WT mice treated with sCT decreased their body weight for the first 2 days, they 
then stop responding to the drug and slightly gained weight during the rest of the treatment 
period. Conversely, RAMP 1/3 KO mice treated with the same dose of sCT gained weight 
after 1 day of treatment but afterwards, between day 2 and day 9, they showed a gradual 
decrease in body weight gain. Indeed, from day 10 until the end of the experiment, a 
significant difference in body weight between RAMP 1/3 WT and RAMP 1/3 KO mice 
treated with sCT was detected (Figure 2A, B). Hence, sCT produced lasting weight loss in 
the RAMP 1/3 KO but not in the RAMP 1/3 WT mice.  
 
For the entire duration of the experiment, cumulative food intake was significantly lower in 
RAMP 1/3 double KO mice treated with the compound NN1213 than the other groups, which 
ate a similar amount of food during the treatment period (Figure 6. C).  
The analysis of food intake on a weekly basis (Figure 6. D) during the treatment period in the 
six groups of mice showed that RAMP 1/3 WT mice treated with the amylin-selective agonist 
NN1213 consumed a significant lower amount of food during the first week compared to the 
other groups, with the exception of RAMP 1/3 double KO group treated with sCT, which 
showed a similar behavior. We didn’t notice the same effect in the second and third week.  
 
Thus, RAMP 1/3 WT decreased their body weight gain, for the first week, when treated with 
NN1213 while RAMP 1/3 KO did not. Even though KO NN1213-treated RAMP 1/3 did not 
decrease their body weight, the treatment decreased their food intake. Further, sCT-treated 
WT mice responded to the treatment by increasing their body weight while RAMP1/3 KO 
28
had the opposite effect and showed a decrease in body weight gain during the first week of 
treatment. However, sCT did not affect food intake in RAMP 1/3 KO. 
 
4.1.3 Effect of amylin-selective agonist NN1213 and sCT in RAMP 1/3 WT and KO 
mice models on blood parameters and body composition  
 
Figure 7: Insulin, Glucagon, GLP-1, Leptin (pg/ml) and Glucose (mmol/l) concentration 
measured in plasma of RAMP 1/3 WT and KO mice after 21 days of treatment with 
vehicle, NN1213 (30 nmol/kg) or sCT (150 nmol/kg) at time of sacrifice. All data are 
presented as mean ±SEM; N= 8/group. Parameters with differing superscript letters offer 
from each other at p<0.05 level by Tukey and Sidak post hoc adjustment after significant 
intergroup differences were found by two-way ANOVA. * Symbols denote significant 
differences between the two genotypes; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
Insulin and glucose plasma levels were lower in RAMP1/3 KO treated with sCT than in WT 
sCT-treated mice (Figure 7A, E). This difference is probably result from the lower body 






































































































































































































































































































































Glucagon plasma concentration was not significantly different between groups (Figure 7B). 
However, RAMP 1/3 double KO treated with NN1213 showed significantly higher GLP-1 
levels than WT treated with sCT (Figure 7C) 
 
WT mice injected with NN1213 had a significant lower leptin concentration in plasma 
compared to the WT receiving vehicle. WT receiving sCT showed a higher leptin 
concentration in comparison to the NN1213 treated group but this difference was not 
statistically significant. RAMP 1/3 KO mice displayed lower leptin levels compared to WT 
mice treated with vehicle or sCT (Figure 7D) but were similar to WT+NN1213 mice.   
 
To assess body composition in the different groups, lean and fat mass were measured using 
CT scan. The region between the vertebrae L1-L6 was evaluated. Figure 8 shows body 
composition (in g) of the six groups of treatment. Lean mass was significantly lower in 
RAMP 1/3 double KO mice compared to the WT cohort, regardless of the treatment received 
which reflects their lower body weight in general. The data showed a trend with a p-value of 
0.06 in the visceral fat mass between RAMP 1/3 WT mice and double KO treated both with 
sCT. 
 
Figure 8: mass of lean, total fat, visceral fat, subcutaneous fat in grams and fat ratio% 
measured by CT scan in RAMP 1/3 WT and KO injected with vehicle, NN1213 and sCT 
for 21 days after 20 weeks on 45% HFD. Parameters with differing superscript letters differ 
from each other at p<0.05 level by Tukey multiple comparisons test after significant 
intergroup differences were found by two-way ANOVA. Data are represented as mean ± 
SEM; N=8/group. 
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4.2. RAMP 3 wild-type and knockout mice 
 
4.2.1 Obesity induction period  
 





Figure 9: Obesity induction period in RAMP 3 WT and KO mice fed with 45% HFD ad 
libitum for 20 weeks A: Weekly body weight (g) in RAMP 3 WT and KO mice over 20 
weeks on 45% HFD. B: Weekly body weight gain (g) in RAMP 3 WT and KO mice over 20 
weeks on 45% HFD. C: Weekly cumulative food intake (kcal) of RAMP 3 WT and KO mice 
over 20 weeks on 45% HFD. D: Biweekly non-fasting blood glucose level (mmol/l) of 
RAMP 3 WT and KO mice maintained on 45% HFD for 20 weeks. All data are expressed as 
mean ± SEM, n=24/group.  Symbols denote significant differences between the two 
genotypes; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
Baseline body weight average was similar (22-24g) in both groups at the beginning of the 
observation time. From week 7 until week 20, RAMP 3 KO mice gained slightly more weight 
compared to RAMP 3 WT mice, but this difference was never significant (Figure 9A).  
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Body weight gain showed no significant difference between the groups throughout the HFD 
period. The average of body weight after 20 weeks on 45% HFD was 50.6 g and 53.2 g for 
RAMP 3 WT and RAMP 3 KO mice respectively (Figure 9B).  
Consistent with body weight results, no significant differences were observed regarding food 
intake between WT and KO mice (Figure 9C). 
Bi-weekly tail blood glucose average measured in the two groups of mice showed that 
between week 14 and week 18, RAMP 3 KO mice had a significantly higher blood glucose 
level compared to RAMP 3 WT mice (Figure 9D). 
 
4.2.2 Effect of amylin-selective agonist NN1213 and sCT in RAMP 3 WT and 
KO mice models after 21 days of treatment 
 
Baseline body weight was not significantly different at the start of the injection period 
(Figure 10A) and body weight remained similar among the groups during the treatment 
period (Figure 10A). However, from day 1 to day 5, body weight gain was decreased in 
RAMP 3 WT mice treated with NN1213 (Figure 10B). A marked decrease in body weight 
gain was also seen in RAMP 3 KO mice treated with sCT between day 1 and day 8 but this 
effect was lost from day 12 onwards, where a rebound effect was noticed. We didn’t observe 
any significant difference among WT and KO treated with the amylin-selective agonist 
NN1213, but as seen on the graph, the drop in body weight gain was more marked, more 
rapid and longer lasting in the WT mice rather than in the KO mice. No significant difference 
between the groups in the cumulative food intake was measured throughout the entire 
experiment (Figure 10D). 
Overall, a decreased in body weight gain in response to NN1213 was observed in RAMP 3 
WT mice while RAMP 3 KO mice responded to sCT by decreasing their body weight gain 




Figure 10: Effect of amylin-selective agonist NN1213 (30 nmol/kg) and sCT (150 
nmol/kg) subchronic treatment (21 days) in RAMP 3 WT and KO mice after an 
induction obesity period of 20 weeks on 45% HFD. A: daily BW (g) of RAMP 3 WT and 
KO mice treated for 21 days with vehicle, NN1213 (30 nmol/kg) and sCT (150 nmol/kg). B: 
daily body weight gain (g) of RAMP 3 WT and KO mice treated daily with vehicle, NN1213 
and sCT for a period of 21 days. C: daily food intake of RAMP 3 WT and KO during 21 days 
of treatment with vehicle, NN1213 and sCT. Mean ± SEM, N=8/group. Parameters with 
differing superscript letters differ from each other at p<0.05 level by Tukey post hoc 
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4.2.3 Effect of amylin-selective agonist NN1213 and sCT in RAMP 3 WT and 





Figure 11: blood glucose level (mmol/l) at time of sacrifice in RAMP 3 WT and KO mice 
after been treated daily for 21 days with vehicle, NN1213 (30 nmol/kg) and sCT (150 
nmol/kg). Data are represented as Mean ± SEM. N=8/group 
 





















RAMP 3 WT RAMP 3 KO
4.3. RAMP 1 wild-type and knockout mice 
 
4.3.1 Obesity induction period 
 
 
Figure 12: Obesity induction period in RAMP 1 WT and KO mice fed with 45% HFD 
ad libitum for 20 weeks. A: Weekly body weight (g) in RAMP 1 WT and KO mice over 20 
weeks on 45% HFD.  B: Weekly body weight gain (g) in RAMP 1 WT and KO mice over 20 
weeks on 45% HFD. C: Weekly cumulative food intake (Kcal) of RAMP 1 WT and KO mice 
over 20 weeks on 45% HFD. D: Non-fasting blood glucose level (mmol/l) of RAMP 1 WT 
and KO mice maintained on 45% HFD  for 20 weeks measured on a bi-weekly base.  All data 
are expressed as mean ± SEM, symbols denote significant differences between the two 
genotypes; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. N = 24 per group. 
 
 
As for the other KO models, the same protocol was repeated in RAMP 1 WT and KO mice.  
Baseline body weight at the beginning of the HFD period was similar (21-23 g) in both 
groups. Overall, we didn’t observe any significant difference during the HFD period, with 
exception of week 16, where RAMP 1 WT mice showed a significantly higher body weight 
compared to the KO mice (Figure 12A).  
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Similarly to the RAMP 3 KO study, 45% HFD had the same effect on body weight gain in 
WT and KO mice (Figure 12B). However food intake was significantly higher in RAMP 3 
KO mice from 13 to 17 and 20-23 weeks-old (Figure 12C). 
No significant difference on blood glucose level was measured between both genotypes 
(Figure 12D).  
 
4.3.2  Effect of amylin-selective agonist NN1213 and sCT in RAMP 1 WT and 
KO mice models after 21 days 
 
 
Figure 13. Effect of amylin-selective agonist NN1213 (30 nmol/kg) and sCT (150 
nmol/kg) subchronic treatment SC (21 days) in RAMP 1 WT and KO mice after an 
induction obesity period of 20 weeks on 45% HFD. A: daily BW (g) of RAMP 1 WT and 
KO mice treated for 21 days with vehicle, NN1213 (30 nmol/kg) and sCT (150 nmol/kg). B: 
daily body weight gain (g) of RAMP 1 WT and KO mice treated daily with vehicle, NN1213 
and sCT for a period of 21 days. C: daily food intake of RAMP 1 WT and KO during 21 days 
of treatment with vehicle, NN1213 and sCT. Data are represented as mean ± SEM; 
N=8/group. Parameters with differing superscript letters differ from each other at p<0.05 
level by Tukey post hoc adjustment after significant intergroup differences were found by 
two-way ANOVA.  
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As shown in figure 13A, the six groups had similar baseline body weight at the start of the 
injection period. During the first week of treatment, RAMP 1 WT and KO treated with 
NN1213 responded to the treatment and gained less weight compared to their respective 
vehicle-treated and sCT-treated mice (Figure 13B). In the second and third week of 
treatment, NN1213-treated RAMP 1 WT and KO mice maintained their reduced body weight 
loss in comparison to the vehicle control group. While NN1213 seemed to induce a greater 
decrease in body weight gain in WT mice compared to KO mice, this difference in effect was 
not significant. sCT had no effect on RAMP 1 WT and KO mice (Figure 13B). 
 
On day 13 of treatment, cumulative food intake of RAMP1 WT receiving sCT was 
significantly increased compared to  WT NN1213 and vehicle-treated mice. This difference 
remained significant until the end of the treatment period (Figure 13C). No other treatment 




Figure 14: blood glucose level (mmol/l) at time of sacrifice in RAMP 1 WT and KO mice 
after been treated daily for 21 days with vehicle, NN1213 (30 nmol/kg) and sCT (150 
nmol/kg). Data are represented as mean ± SEM. N=8/group 
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Figure 15: Nose-Anus length of RAMP 1 WT and KO vs. RAMP 3 WT and KO mice 
(cm) measured at time of sacrifice Data are represented as mean ± SEM. N=8/group. 
Parameters with differing superscript letters differ from each other at p<0.05 level by Tukey 
post hoc adjustment after significant intergroup differences were found by two-way ANOVA.  
 
Since starting body weight was much lower in RAMP 1 WT/KO mice, nasal-anal length of 
RAMP 1 and RAMP 3 mice at the end of the treatment period was measured. Thus, RAMP 1 
WT and KO mice were significantly shorter than RAMP 3 WT and KO mice.  No treatment 














































The purpose of this study was to assess the weight loss efficacy of the amylin selective 
agonist (NNCO1741213) in the three RAMP mouse models- RAMP 1/3, RAMP 3, RAMP 1- 
WT and KO compared to that of sCT to investigate the role of the different RAMPs in 
modulating the pharmacological effects and potential differences of amylin selective agonist 
versus dual amylin calcitonin receptor agonist. 
Our results showed that RAMP 1 and RAMP 3 are involved in the mechanism of action of 
NN1213 in mice and both receptor isoforms mediate the action of the amylin selective 
agonist on body weight and food intake. Indeed, we saw a weight – lowering effect of 
NN1213 in all WT mice and in the KO mouse models where at least one RAMP (RAMP 1 or 
RAMP 3) was expressed.  
Further, we provided evidence that sCT in mice has an effect on body weight and food intake 
only in the absence of RAMP 3. In addition to that our results suggest that sCT does not have 




5.1 Effect of 20 weeks 45% high fat diet on body weight and food intake in 
RAMP mice models 
 
In the first part of the study, we investigated the effect of 20 weeks of HFD ad libitum in the 
three mouse models. Our results show surprisingly that RAMP 1/3 KO mice gained 
significantly less weight than the WT during 20 weeks of 45% HFD. In the RAMP 3 model, 
body weight of KO and WT mice was similar for the entire duration of HFD period. Last, in 
the RAMP 1 model, we noticed that RAMP 1 KO gained less weight from week 14 until the 
end of the observation period. The same effect was also noticeable in the cumulative food 
intake in both RAMP 1 and 1/3 KO models with both KO eating less HFD than their WT 
littermates while RAMP 3 KO mice ate the same amount as WT. Finally, only RAMP 1/3 
KO mice had lower blood glucose level than the WT, reflecting the lower body weight and 
the lower amount of food consumed. These effects remained significant until the end of the 
entire study. 
Opposite to what we have shown in our previous study where RAMP 1/3 KO gained more 
weight than WT when fed 45% HFD at 8 weeks-old
58
, here the mice were put on HFD at 4 
weeks of age and  presumably had not yet reached puberty at that time. Based on our results, 
the lower body weight gain and lower food intake on 45% HFD in RAMP 1/3 and RAMP 1 
39
KO mice suggest that these mice may become resistant to a high fat palatable diet regimen 
when exposed very early in life. 
One other consideration to be discussed is that RAMP 1 mice were generally lighter than the 
other two KO models and our results showed also that RAMP 1 were smaller than RAMP 3 
KO mice. These differences could be explained by a breeding effect or by the role RAMP 1 
vs. RAMP 3 on growth and body weight homeostasis. It is known that chow diet-fed RAMP 
1 overexpressing transgenic mice are leaner, lighter, have increased energy expenditure and 
higher body temperature
59
, but we surprisingly also found out that 45% HFD-fed RAMP 1 
KO mice were leaner than the WT mice. It is possible that the germ-line deletion of RAMP 1 
induces developmental effects or that the depletion of RAMP 1 in altering other signaling 
pathway such as CGRP 
60, 61 
plays a role in this metabolic effect. Our previous study on chow 
diet showed that even though RAMP 1 KO weigh the same as WT mice, they were fatter than 
the WT mice suggesting that RAMP 1 mediate fat storage and utilization
58
. To explain the 
“resistance” of RAMP 1 KO to 45% HFD, further experiments are required to understand the 
underlying mechanism regulating energy homeostasis in RAMP 1 KO mice. 
On chow diet, male RAMP 3 WT and KO are known to display similar body weight and food 
intake
62
. Similar to our study with male mice, female RAMP 3 WT and KO mice fed 32% 
HFD also had the same body weight and food intake. These female KO mice also had the 
same glucose tolerance and body composition compared to WT
62
. However, contrary to our 
study, Liu et al did not assess the effect of HFD in male mice. 
 
5.2 Effect of the subchronic NN1213 and sCT treatment in WT/RAMP KO mice 
models 
 
5.2.1 RAMP 1/3 
 
Our results clearly demonstrated that RAMP 1/3 WT mice were sensitive to the NN1213 
compound, at least in the first 5 days of treatment. Then we observed a rebound phenomenon 
and mice regained their body weight by day 15 of treatment. This initial decrease in body 
weight was accompanied by an anorectic effect during the first week of treatment.  
While sCT had a minimal effect in the WT mice, sCT was efficient in the KO mice eliciting a 
body weight loss in the first 7 days of experiment, while thereafter, as observed for RAMP 
1/3 WT receiving NN1213, mice started to regain some weight and reached their initial body 
weight measured by the end of the treatment period. This temporary decrease in body weight 
40
was also accompanied by an anorectic effect during the first week of treatment. Furthermore, 
this decrease in body weight gain and food intake was correlated with a decrease in blood 
glucose and insulin in  sCT-treated KO mice compared to the sCT-treated WT mice.  
Furthermore, WT and KO mice display significantly different body weight at the start of the 
experiment with KO mice being lighter than WT mice. This difference in body weight also 
correlated with glucose levels with WT mice having an overall higher glucose level than 
RAMP 1/3 KO mice. The body composition analysis confirmed that regardless of the 
treatment received, RAMP 1/3 KO mice were leaner compared to the WT cohort. Although 
these differences didn’t reach significance, WT mice receiving NN1213 tended to be leaner 
in comparison to the other WT groups but still heavier than the KO. Interestingly, body fat 
mass analysis didn’t show any differences between WT and KO mice and displayed a similar 
fat ratio (%), similar subcutaneous fat and there was only a trend (P=0.06) in visceral fat 
between WT and KO receiving both sCT. Based on these results, we expected no differences 
in leptin levels between the groups; nevertheless we clearly saw that WT mice treated with 
NN1213 had significant lower plasma leptin level compared to the other WT groups. Thus 
even though there was no difference in subcutaneous tissue mass, leptin levels were lowered  
in WT NN1213-treated mice suggesting that NN1213 may act on leptin production since 
subcutaneous fat tissue is the major source of leptin in the blood
63
. It is also possible that 
subcutaneous fat pads were decreased in WT-treated mice but since we only quantified it 
from L1 to L6 we might have missed this difference between the groups. 
In addition, we observed that all KO mice had significant lower amount of plasma leptin 
level in comparison the WT vehicle-treated group further highlighting their lower body 
weight on 45% HFD. 
 
Together these data suggest that subchronic sCT only had an effect in the RAMP 1/3 KO 
mice and that NN1213 elicited body weight loss only in the WT mice. Thus the NN1213 is 
specific to the amylin receptor while sCT can act when only CTR is present. To understand 
why subchronic sCT does not elicit any weight loss and does not decrease food intake in WT 
mice require further investigation. 
 
5.2.2 RAMP 3 
 
RAMP 3 WT treated with NN1213 and RAMP 3 KO mice treated with sCT showed a similar 
trend throughout the entire experiment. Our results showed a strong body weight loss during 
41
the first week of treatment in both groups. Then this effect was partly lost and a rebound 
phenomenon was observed in both groups. Interestingly, compared to RAMP 1/3 KO, 
NN1213 seemed to have some effect in the RAMP 3 KO mice, leading to a body weight loss 
of approximately 2g. Nevertheless, compared to RAMP 3 WT, RAMP 3 KO were less 
sensitive to NN1213. As already observed in the RAMP 1/3 WT mice, sCT didn’t have any 
effects in the RAMP 3 WT mice. Our findings showed no differences in food intake amongst 
all the groups.  Finally, we did not see any increase in body weight gain in vehicle-treated 
group and WT treated with sCT, compared to what we have seen in the double KO group. 
The single RAMP3 KO/WT colony treated with vehicle and sCT maintained their body 
weight constant whereas the double KO mice (RAMP 1/3 KO) treated with vehicle and sCT 
gained more weight. We could not find any explanation for this discrepancy. 
 
5.2.3 RAMP 1 
 
RAMP 1 WT mice treated with NN1213 showed more weight loss in comparison to the other 
vehicle and sCT-treated WT mice. WT 1213-treated mice also lost significantly more weight 
compared to KO receiving sCT. In fact, sCT had no effect neither in the WT nor in the KO 
mice.  
In addition, RAMP 1 KO mice were also responsive to NN1213, although this effect was less 
pronounced in comparison to the WT receiving NN1213. The response of these mice was 
significant in comparison to KO mice receiving sCT. Our results showed that the main 
difference in the RAMP 1 KO/WT mice colony is that, compared to the other two groups, 
that they were not responsive to the effect of sCT, regardless of the genotype. This result was 
not present in RAMP 1/3 and RAMP 3 mice colonies, where the KO mice were both 
sensitive to sCT. This is in accordance to our recently published study where acute sCT did 
not induce any anorectic effect in the RAMP 1 KO mice
58
.  
Overall, we also observed that mice receiving sCT ate more than the others, this effect was 
noticeable especially in the second half of treatment and similar to what was observed in 
RAMP1/3 KO/WT mice.  
 
5.3 Comparison between the three WT and KO mice models 
 
Our findings showed that NN1213 elicited body weight loss in each of the WT models 
receiving NN1213 at a dose of 30 nmol/kg once daily for 21 days.  
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The body weight loss was between -2g and -3g for all the WT-treated mice. WT NN1213-
treated mice lost most of their weight in the first 5 days of treatment and this weight loss was 
maintained for the RAMP 1 WT and RAMP 3 WT. However even though the WT mice were 
issued from the RAMP 3 breeding colony, we observed that RAMP 1/3 WT mice treated 
with NN1213 lost more weight in the first 5 days of treatment, then, during the rest of the 
experiment we observed a rebound phenomenon where the animals constantly regained 
weight and between day 17 and day 18 they reached the initial body weight (day 0). At 
sacrifice, the animals weight exceeded the initial body weight. A difference in breeding 
generation might explain this difference between the 2 experiments. 
Thus to conclude, when given for a prolonged period NN1213 shows the strongest effect on 
mice in the first 5-6 days of treatment. Then this effect goes partly lost generating a rebound 
phenomenon where the animals generally regain some weight.  
 
NN1213 was also able to lower body weight in RAMP 3 and RAMP 1 KO mice, but not in 
RAMP 1/3 double KO mice. What we noticed was that the compound NN1213 caused more 
body weight loss in RAMP 3 KO (-2g) animals than RAMP 1 KO (-1g). We may thus 
conclude that RAMP 1 may be the main sub-unit mediating the action of NN1213. 
 
Conversely, sCT 150 nmol/kg injected subcutaneously daily for a period of 21 days does not 
induce body weight loss in WT mice. Indeed, in RAMP 1/3 WT mice we noticed that after a 
first period where the natural DACRA seemed to have an effect (first 3 days of treatment), 
the WT mice started to regain weight and at the end of the experiment, the body weight of the 
animals was higher than the one measured at the beginning of the experiment. A similar 
effect of sCT was observed in the RAMP 1 WT model, but the body weight gain in this group 
was lower in comparison to that gained in the RAMP 1/3 WT. RAMP 3 WT lost weight in 
the first 3 days of treatment, then they slightly regained weight, but the body weight of these 
animals at the end of the experiment was similar to the baseline body weight measured after 
20 weeks of HFD. Overall subchronic sCT had little to no effect in WT mice while many 
studies have shown that acute sCT exerts a strong anorectic effect, here
64
 suggesting that the 
accumulation of sCT at the receptor level may induce a desensitization. On the contrary, sCT 
had an effect in both RAMP 1/3 double KO and RAMP 3 KO mice but no effect at all in the 
RAMP 1 KO mice. All together, these results indicate that the absence of RAMP 3 promotes 
the weight lowering effect of sCT in mice.  
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Based on these findings we observed two main differences between the action of amylin 
selective analogues (NN1213) and dual amylin selective agonists (sCT) in mice: an amylin 
selective agonist can elicit body weight in the presence of one or both RAMP 3 and RAMP 1, 
showing more effect when both RAMPs are present, while the DACRA sCT can elicit body 
weight loss only in the absence of RAMP 3, having no effect at all in the WT models and in 
the RAMP 1 KO model.  
 
5.4. Limitations of the study 
 
5.4.1 Differences between rats and mice 
 
Several studies have demonstrated that sCT, other DACRA compounds or amylin and its 
analogs are able to induce long term weight loss in diet induced obese rats
50, 55, 56
. Rats 
treated s.c. subchronically with one of the above-mentioned peptides loose weight and 
transiently reduce their food intake in a dose-dependent manner. For example, rats treated for 
56 days with 2.5 ug/kg KBP-089 (DACRA) s.c. showed a body weight loss of 17%. 
Moreover, KBP-089 reduced fat depot size and fat accumulation in liver and in muscles
56
. 
Other two DACRA have been produced: KBP-088 and KBP-042 which are also able to 
reduce body weight when injected or given orally in a sustained and dose-dependent manner; 
additionally they also reduce white adipose tissue mass and adiposity hypertrophy
65, 55
.  
Unpublished data by Novo Nordisk indicated that diet-induced obese mice respond 
differently to both amylin and sCT analogues than diet-induced obese rats. Treatment of diet-
induced obese mice with amylin analogs induces a minor dose-dependent reduction in body 
weight during the first 1-3 days of treatment, which is more or less sustained during the 
remaining treatment period. On the contrary, after 3 days of treatment, animals treated with 
sCT-based analogues regain or surpass the body weight of vehicle controls in a dose-
responsive manner. The results in our study suggest that RAMP WT mice are not sensitive to 
sCT and that sCT does only elicit body weight loss in the absence of RAMP 3, suggesting a 
role of RAMP3 in the resistance to sCT action in mice. In mice, it is not known how the 
amylin receptors are expressed and how they exactly work. Indeed it is still unknown which 
RAMPs are expressed in which brain area, how they interact with CTR and with which 
RAMPs these DACRA mostly interact with and how is the signaling pathway regulated. The 




While the present study has shed some light on the specific role of RAMP in mediating the 
effect of DACRA and amylin selective analogue, further studies need to be conducted to 
investigate the role and the exact expression of AMY1-3 in mice to properly understand their 
mechanism of action in mouse models.  
 
5.4.2 Role of RAMP 2 
 
The role of RAMP 2 combined with CTR composing AMY2 is not well investigated. Unlike 
RAMP 1 and RAMP 3 KO mouse models which survive during embryonic development and 
in the adulthood, RAMP 2 KO mice are embryonically lethal, showing generalized edema
66
. 
Several studies demonstrated that RAMP 2 is essential for angiogenesis and for the 
development and integrity of a functional lymphatic system
67, 68, 69
. Knocking out the gene 
responsible for the expression of RAMP 2 causes lymphatic and blood vessels defects. 
These findings indicate that endogenous expression of RAMP 1 and RAMP 3 are not able to 
compensate for the physiological function of RAMP 2
66
. In contrast, global deletion of either 
RAMP 1 or RAMP 3 does not affect survival, perhaps because the expression of other 
RAMPs and particularly RAMP2 is able to compensate for their absence and their loss of 
function
66
. Consequently, no global RAMP 2 KO mouse model can be generated to 
investigate the role of RAMP 2. This limits the characterization of this protein in modulating 
the expression of amylin receptor and in the pharmacological role of AMY2 in the control of 
food intake and body weight when interacting with amylin, amylin agonists and dual amylin 
and calcitonin receptor agonist. 
 
5.4.3 Overexpression of RAMPs when one knocked out  
 
If one RAMP is knocked out, we may expect the other two to be overexpressed. Based on 
this concept, we may expect that RAMP 3 KO mice showed an overexpression of RAMP 1 
and RAMP 2 trying to compensate the loss of function of RAMP 3. Unfortunately, we don’t 
know if RAMP 2 was elevated on our KO models. What we observed was that RAMP 3 and 
1 WT and KO mice had similar body weight for the entire duration of the experiment 
suggesting that the depletion of only one RAMP does not affect body weight. On the 
contrary, previous studies
59,70,66
 demonstrated that RAMP 1 overexpression in mice leads to 
lower body weight and increased energy expenditure; transgenic mice that overexpressed 
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RAMP 1 mice are leaner and lighter in comparison to the WT. Previous studies also 
demonstrated that mice overexpressing RAMP 2 exhibited differences only in the vascular 
system
66
. Further analysis about the expression pathways, compensatory mechanisms and 
expression sites of RAMPs will provide more information and definitive answers
68
.  
Overexpression of RAMP 3 has not been investigated yet.  
 
 
In summary, our findings suggest that in mice RAMP 1 and RAMP 3 partly mediate the 
effect of an amylin selective agonist and that a dual amylin-calcitonin receptor agonist is able 
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